What are the differences between the sat and satF virulence genes in Escherichia coli and how do they affect clinical management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Sat vs SatF Virulence Genes in E. coli

Critical Clarification

The provided evidence discusses only the sat gene and its protein product (Sat), with no mention of a distinct "satF" gene. Based on available research, satF does not appear to be a recognized separate virulence gene in E. coli literature. The question may reflect confusion about nomenclature or refer to variants/alleles of the sat gene itself.

The Sat Virulence Gene

Gene Identity and Function

  • Sat (secreted autotransporter toxin) is a 107-kDa serine protease autotransporter encoded by a 3885 bp gene producing a 142 kDa precursor protein 1

  • The protein belongs to the SPATE (Serine Protease Autotransporters of Enterobacteriaceae) family with three characteristic domains: a 49 amino acid signal sequence, a 107 kDa passenger domain with serine protease activity (GDSGSG consensus site), and a 30 kDa C-terminal autotransporter domain 1

Clinical Significance and Pathogenic Role

Sat functions as a major virulence factor in extraintestinal pathogenic E. coli (ExPEC), particularly in bloodstream infections and urinary tract infections, through both direct cytotoxic effects and immune system evasion. 2

Cytotoxic Mechanisms:

  • Vacuolating cytotoxin activity on bladder (CRL-1749) and kidney (CRL-1573) epithelial cells, causing cell elongation, loosening of cellular junctions, and significant cytoplasmic vacuolation 3

  • F-actin disruption leading to cell detachment in polarized intestinal cells during enteroaggregative E. coli (EAEC) infection 4

  • Differential tissue sensitivity: Endothelial cells (HUVEC) show greater sensitivity to Sat than urinary or intestinal tract cells, suggesting enhanced virulence potential in bloodstream infections 4

Immune Evasion Properties:

  • Cleaves multiple complement system proteins (all tested substrates except C1q) in a dose- and time-dependent manner, affecting all three complement pathways 2

  • Confers serum resistance: E. coli strains producing Sat survive in normal human serum, and even non-pathogenic E. coli DH5α survives in serum pre-incubated with Sat 2

  • Reduces mortality in sepsis models by 50% when sat is knocked out, demonstrating critical role in bloodstream infection establishment 2

Epidemiology and Distribution

  • Highly prevalent in uropathogenic E. coli (UPEC): Significantly more common in strains causing acute pyelonephritis compared to fecal commensal strains (P = 0.029) 1

  • Detected in 93.7% of EAEC strains harboring the sat gene 4

  • Found in 34.8% of ECOR collection strains from healthy human stools, with high prevalence in phylogenetic groups D and B2 (associated with extraintestinal infections) 5

  • Present in neonatal septicemia and meningitis isolates 4

Pathological Evidence

  • In vivo kidney damage: Murine urinary tract infection models show dissolution of glomerular membranes and vacuolation of proximal tubule cells in wild-type CFT073 infections, but not with sat mutants 3

  • No effect on colonization: Sat is not required for intestinal colonization, and sat mutants actually outcompete wild-type strains in streptomycin-treated mouse models 5

Context-Dependent Virulence

A critical caveat: Sat does not universally function as a virulence factor across all E. coli strains. In the probiotic E. coli Nissle 1917 (EcN), despite sat expression and active serine protease secretion, the protein does not cause pathogenic effects 5. EcN secretes other factors that protect against Sat-mediated barrier disruption, demonstrating that virulence depends on the complete genetic background of the pathotype, not sat alone 5.

Clinical Management Implications

  • Sat presence indicates enhanced pathogenic potential in ExPEC strains, particularly for bloodstream and urinary tract infections requiring more aggressive antimicrobial therapy

  • Elicits strong antibody responses during infection, as demonstrated in murine models 1

  • Consider Sat-producing strains as higher risk for severe complications including sepsis, given the 50% mortality difference in animal models 2

Related Questions

What is the role of the satF (sat) virulence gene in Escherichia coli and how should infections caused by satF‑positive strains be managed?
What are the differences between the sat and satf virulence genes in Escherichia coli and how do they affect pathogenicity?
What is the significance and prevalence of the fliCD and satF genes in uropathogenic Escherichia coli?
What are the functions and clinical significance of the sat gene versus the satF gene in Escherichia coli?
What is the recommended workup and treatment for a patient presenting with new‑onset dysphasia?
What are the normal ranges for sperm concentration, total ejaculate count, progressive motility, and morphology in healthy adult males?
In older women with hypertension, obesity, diabetes, chronic kidney disease, or atrial fibrillation, can heart‑failure with preserved ejection fraction and a normal left‑ventricular end‑diastolic pressure cause an elevated pulmonary capillary wedge pressure during right‑heart catheterization for suspected Group 2 pulmonary hypertension?
What is the recommended first‑line pharmacologic treatment and dosing for a 17‑year‑old female with bipolar disorder, assuming normal renal, thyroid and cardiovascular function?
In a patient with renal impairment who has a urinary tract infection, can ceftriaxone be used without dose adjustment, and what is the appropriate dosing regimen?
What is the role of the satF (sat) virulence gene in Escherichia coli and how should infections caused by satF‑positive strains be managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.